Guifeng Ma1, Yan Sun2, Shiwen Fu3. 1. Department of Diagnostic Ultrasound, The Affiliated Hospital of Weifang Medical College Weifang, China. 2. Department of Diagnostic Ultrasound, The Fouth Hospital of Jinan Jinan, Shandong, China. 3. Department of Diagnostic Ultrasound, The People's Hospital of Weifang Weifang, China.
Abstract
BACKGROUND/AIMS: Gemcitabine (GEM) is the first-line chemotherapy in patients with unresectable pancreatic cancer. However, the clinical outcomes of this regimen are still unsatisfactory in prolonging survival. Resistant to GEM is one of the reasons for poor prognosis. Therefore, looking for molecular biomarkers to predict chemosensitivity to GEM is important for treatment in unresectable pancreatic cancer patients. The aim of this study was to analyze S100A4 mRNA in tissues of unresectable pancreatic cancer obtained by endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA), and to determine the relation between S100A4 mRNA level and chemosensitivity to GEM. METHODS: The analysis was performed on samples from 36 patients with unresectable pancreatic cancer who were treated with gemcitabine alone. The patients were assigned to receive GEM at 1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 4 weeks. mRNA was extracted for S100A4 mRNA assay from patients above by EUS-FNA before GEM-treatment. The 36 patients were divided into the following two groups. Patients with partial response and those with stable disease whose tumor markers decreased by 50% or more were classified as the effective group. The rest of patients were classified as the non effective group. The relationship between GEM efficacy and S100A4 mRNA expression was then examined by chi-squared test. RESULTS: S100A4 mRNA showed a significant correlation with GEM efficacy. Patients in the effective group had low S100A4 mRNA expression, whereas patients in non-effective group had high S100A4 mRNA expressions (P = 0.0059). CONCLUSION: S100A4 mRNA level analyzed in EUS-FNA samples is an important molecular biomarker for prediction of chemosensitivity to GEM in unresectable pancreatic cancer.
BACKGROUND/AIMS: Gemcitabine (GEM) is the first-line chemotherapy in patients with unresectable pancreatic cancer. However, the clinical outcomes of this regimen are still unsatisfactory in prolonging survival. Resistant to GEM is one of the reasons for poor prognosis. Therefore, looking for molecular biomarkers to predict chemosensitivity to GEM is important for treatment in unresectable pancreatic cancerpatients. The aim of this study was to analyze S100A4 mRNA in tissues of unresectable pancreatic cancer obtained by endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA), and to determine the relation between S100A4 mRNA level and chemosensitivity to GEM. METHODS: The analysis was performed on samples from 36 patients with unresectable pancreatic cancer who were treated with gemcitabine alone. The patients were assigned to receive GEM at 1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 4 weeks. mRNA was extracted for S100A4 mRNA assay from patients above by EUS-FNA before GEM-treatment. The 36 patients were divided into the following two groups. Patients with partial response and those with stable disease whose tumor markers decreased by 50% or more were classified as the effective group. The rest of patients were classified as the non effective group. The relationship between GEM efficacy and S100A4 mRNA expression was then examined by chi-squared test. RESULTS:S100A4 mRNA showed a significant correlation with GEM efficacy. Patients in the effective group had low S100A4 mRNA expression, whereas patients in non-effective group had high S100A4 mRNA expressions (P = 0.0059). CONCLUSION:S100A4 mRNA level analyzed in EUS-FNA samples is an important molecular biomarker for prediction of chemosensitivity to GEM in unresectable pancreatic cancer.
Authors: Patrick C Mahon; Patrick Baril; Vipul Bhakta; Claude Chelala; Krishna Caulee; Tomohiko Harada; Nicholas R Lemoine Journal: Cancer Res Date: 2007-07-15 Impact factor: 12.701
Authors: Moon Jae Chung; Se Woo Park; Seong-Hun Kim; Chang Min Cho; Jun-Ho Choi; Eun Kwang Choi; Tae Hoon Lee; Eunae Cho; Jun Kyu Lee; Tae Jun Song; Jae Min Lee; Jun Hyuk Son; Jin Suk Park; Chi Hyuk Oh; Dong-Ah Park; Jeong-Sik Byeon; Soo Teik Lee; Ho Gak Kim; Hoon Jai Chun; Ho Soon Choi; Chan Guk Park; Joo Young Cho Journal: Clin Endosc Date: 2021-03-24
Authors: Moon Jae Chung; Se Woo Park; Seong-Hun Kim; Chang Min Cho; Jun-Ho Choi; Eun Kwang Choi; Tae Hoon Lee; Eunae Cho; Jun Kyu Lee; Tae Jun Song; Jae Min Lee; Jun Hyuk Son; Jin Suk Park; Chi Hyuk Oh; Dong-Ah Park; Jeong-Sik Byeon; Soo Teik Lee; Ho Gak Kim; Hoon Jai Chun; Ho Soon Choi; Chan Guk Park; Joo Young Cho Journal: Gut Liver Date: 2021-05-15 Impact factor: 4.519